Advertisement
News
Advertisement

CONMED Corporation Launches New Products at 2012 Digestive Disease Week Conference and SGNA Annual Course

Mon, 05/21/2012 - 12:45pm
The Associated Press

(http://www.conmed.com )

CONMED Corporation (NASDAQ: CNMD) today announced that its CONMED

Endoscopic Technologies business unit will formally launch multiple

new medical devices at the Digestive Disease Week (DDW@) conference in

San Diego, CA on May 20-22, 2012, as well as the Society for

Gastroenterology Nurses and Associates (SGNA) Annual Course in

Phoenix, AZ on May 18-23, 2012.

"CONMED has been energizing therapeutic endoscopy and provided

important medical solutions to the global GI community for over 20

years," said Mark Donovan, Vice President of the CONMED Endoscopic

Technologies business unit. "The launch of six new, important products

at DDW and SGNA this week underscores our continued commitment to

delivering critical advancements for GI physicians, and their

patients."

The following products are being launched at DDW/SGNA:

ClearView?EUS FNA System - CONMED Endoscopic Technologies ClearView?

Endoscopic Ultrasound (EUS) needle features Twist Lock Technology

(TLT?), which allows the physician to adjust the sheath and needle

piston with one hand, while current technology requires thumb screws

to secure the pistons. ClearView's laser-treated needle tip also

provides enhanced visualization for the physician. CONMED Endoscopic

Technologies offers a full range of EUS needles -- 19g, 22g and 25g.

EUS is one of the fastest growing segments in the GI market.

BiCap III? - BiCap III? Electrosurgical Unit (ESU) incorporates

CONMED's Dynamic Response technology, which reacts to different tissue

impedances in less than one millisecond, ensuring a consistent

delivery of power and clinical effect while minimizing surrounding

tissue damage. This GI-focused unit brings modern day ESU Technology

into the GI Lab in an economical and user-friendly format.

EnTake?PEG - CONMED has extended its highly sought after EnTake?

gastrostomy product line to include initial placement kits without

drugs. Facilities often already have lidocaine on hand and, therefore,

have no need for it to be included in the kits. Without the lidocaine,

EnTake? ND offers an economical solution, as well as longer shelf

life.

ClearGuard? - The ClearGuard? Biopsy Valve is designed to help reduce

cross-contamination from bodily fluids and eliminates the need for

reprocessing valves. ClearGuard helps maintain luminal insufflations

while restricting backflow during a procedure.

Optimizer?Polyp Trap - CONMED Endoscopic Technologies has extended its

Optimizer Polyp Trap line, another highly sought after product. The

Optimizer Polyp Trap is renowned for its versatility with four

independent, selectable trap chambers, along with four multiple direct

bypass channels. Each chamber has visual markers for identification.

Optimizer Polyp Trap is individually packaged for single patient use

to reduce the risk of cross-contamination.

Enteroscope SpiderNet? - CONMED Endoscopic Technologies has extended

its SpiderNet line with the introduction of the enteroscopic version.

SpiderNet's pouch delicately closes around the specimen during

retraction, reducing the risk of loss or damage. When wet, the net

material becomes translucent for enhanced endoscopic visibility. An

atraumatic net configuration, SpiderNet minimizes the potential for

minced specimen or crushed artifact.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical

devices and equipment for minimally invasive procedures and

monitoring. The Company's products serve the clinical areas of

arthroscopy, powered surgical instruments, electrosurgery, cardiac

monitoring disposables, endosurgery and endoscopic technologies. They

are used by surgeons and physicians in a variety of specialties

including orthopedics, general surgery, gynecology, neurosurgery, and

gastroenterology. Headquartered in Utica, New York, the Company's

3,400 employees distribute its products worldwide from several

manufacturing locations.

Forward Looking Information

This press release contains forward-looking statements based on

certain assumptions and contingencies that involve risks and

uncertainties. The forward-looking statements are made pursuant to the

safe harbor provisions of the Private Securities Litigation Reform Act

of 1995 and relate to the Company's performance on a going-forward

basis. The forward-looking statements in this press release involve

risks and uncertainties which could cause actual results, performance

or trends, to differ materially from those expressed in the

forward-looking statements herein or in previous disclosures. The

Company believes that all forward-looking statements made by it have a

reasonable basis, but there can be no assurance that management's

expectations, beliefs or projections as expressed in the

forward-looking statements will actually occur or prove to be correct.

In addition to general industry and economic conditions, factors that

could cause actual results to differ materially from those discussed

in the forward-looking statements in this press release include, but

are not limited to: (i) the failure of any one or more of the

assumptions stated above, to prove to be correct; (ii) the risks

relating to forward-looking statements discussed in the Company's

Annual Report on Form 10-K for the fiscal year ended December 31,

2011; (iii) cyclical purchasing patterns from customers, end-users and

dealers; (iv) timely release of new products, and acceptance of such

new products by the market; (v) the introduction of new products by

competitors and other competitive responses; (vi) the possibility that

any new acquisition or other transaction may require the Company to

reconsider its financial assumptions and goals/targets; (vii)

increasing costs for raw material, transportation of litigation;

(viii) the risk of a lack of allograft tissues due to reduced

donations of such tissues or due to tissues not meeting the

appropriate high standards for screening and/or processing of such

tissues; and/or (ix) the Company's ability to devise and execute

strategies to respond to market conditions.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading